BioSpace News Archive

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, provides a corporate update.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that it has entered into a partnership with AFT Pharmaceuticals to co-develop HY-090, a novel locally-acting product candidate for the treatment of Burning Mouth Syndrome.

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced 510(k) clearance of its next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).

Biodexa Pharmaceuticals PLC announced the closing of an underwritten public offering of units for gross proceeds of approximately $6.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Biodexa.

Pharma-Bio Serv, Inc. today announced that the Board of Directors approved a Special Dividend of $0.075 per share for Shareholders.

Guardant Health, Inc., a leading precision oncology company, announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages for the sale of 3,387,446 shares of its common stock in a registered direct offering at an offering price of $26.77 per share.

Kelyniam Global, a maker of custom cranial implants, announced results for its third quarter ended September 30, 2023.

Medicenna Therapeutics Corp. announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of the common share purchase warrants of the Company originally issued on December 21, 2018.

Ono Pharmaceutical Co., Ltd. announced that it has entered into a discovery collaboration agreement with EVQLV, INC, to generate novel antibodies against multiple targets selected by Ono, for the development of innovative antibody drugs.

Polaris Group announced that its board approved to increase the acquisition of Genovior Biotech’s shares to 100%.